Canada not recommending AstraZeneca's (AZN) Lynparza for reimbursement - Bloomberg

October 5, 2016 8:15 AM EDT
Get Alerts AZN Hot Sheet
Trade AZN Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

AstraZeneca (NYSE: AZN) says Canada not recommending Lynparza for reimbursement, according to Bloomberg.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Trader Talk

Add Your Comment